According to the latest IMARC Group report, entitled “Generic Drugs Market in Latin America: Industry Trends, Share, Size, Growth, Opportunities and Forecast 2021-2026“, the Latin America Generic Drugs Market Expected to Show High Growth in the Period 2021-2026Generic drugs are identical to brand name drugs and generally have therapeutic effects equivalent to pharmaceutical specialties. Since they contain the same active ingredients, they are identical in terms of quality, route of administration, dosage and side effects. On top of that, they are cost effective because they don’t include clinical trials and the cost of research. However, they require prior authorization from regulatory authorities after the patent expiration of brand-name drugs in order to market their products.
Request a PDF sample of this report: https://www.imarcgroup.com/latin-america-generic-drug-market/requestsample
The market in Latin America is mainly driven by the significant growth of the pharmaceutical industry. At the same time, the increasing prevalence of chronic diseases in individuals, such as Alzheimer’s disease, rheumatoid arthritis and osteoarthritis, is driving the sales of generic drugs in the region. In addition, the increasing investments by the government of several countries in the region to modernize their existing health infrastructure and promote the production of generic drugs are positively influencing the growth of the market. Some of the other factors contributing to the growth of the market in the region include the increase in the geriatric population and the expiration of the patents of several successful drugs. Looking ahead, IMARC Group expects the global market to continue its robust growth during the forecast period (2021-2026)
As the novel coronavirus (COVID-19) crisis takes over the world, we are constantly monitoring changes in the markets, as well as the industrial behaviors of consumers around the world and our estimates on the latest market trends and forecasts are made afterwards. examining the impact of this pandemic.
Marlet Segmentation:
Breakdown by segment:
- Unbranded generics
- Brand generics
Breakage by therapy zone:
- Central nervous system
- Cardiovascular
- Dermatology
- Genitourinary / Hormonal
- Respiratory
- Rheumatology
- Diabetes
- Oncology
- Others
Breakdown by drug delivery:
- Oral
- Injectables
- Dermal / Topical
- Inhalers
Breakdown by distribution channel:
- Retail pharmacies
- Hospital pharmacies
Breakdown by country:
- Brazil
- Mexico
- Argentina
- Colombia
- Chile
- Peru
- Others
Ask the analyst for customization and explore the full report with table of contents and list of figures: https://bit.ly/2R6YcKb
We update our reports, if you want the latest primary and secondary data (2021-2026) with cost module, business strategy, distribution channel etc. Click request free sample report, the published report will be delivered to you in PDF format by email within 24-48 hours.
Highlights of the report:
- Market performance (2015-2020)
- Market Outlook (2021-2026)
- Market trends
- Market drivers and success factors
- The impact of COVID-19 on the global market
- Value chain analysis
- Global market structure
- Complete mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as part of the customization.
Related IMARC Group Reports:
Preclinical CRO market report by 2021-2026
Report on Nucleic Acid Labeling Market by 2021-2026
About Us
The IMARC group is a leading market research company providing management strategies and market research worldwide. We partner with clients across industries and regions to identify their most exciting opportunities, address their most critical challenges and transform their businesses.
IMARC’s information products include leading business, scientific, economic and technological developments for business leaders in the biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism and nanotechnologies. We also provide cost model and manufacturing configuration project reports through Syndicated Analytics, a subsidiary of IMARC Group.
Our offerings include comprehensive market information in the form of research reports, production cost reports, feasibility studies and consulting services. Our team, which includes experienced researchers and analysts from a variety of industries, is dedicated to delivering high-quality data and information to our customers, ranging from small and medium-sized businesses to Fortune 1000 companies.
Contact us:
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Phone number: (D) +91 120 433 0800
Americas: – +1 631 791 1145 | Africa and Europe: – + 44-702-409-7331 | Asia: + 91-120-433-0800, + 91-120-433-0800
![Nanoparticle Market 2022 [Future SCOPE] to gain new momentum with Bristol-Myers Squibb Company, Johnson & Johnson, Amgen](https://img.einnews.com/ampsize/326373/nanoparticles.jpeg)
